Maegim한국어

대한약품

023910KOSDAQSector: Pharma & Biotech
₩25,500▲ 0.99%Market cap ₩153.0BAs of Jul 21, 2026 close · updated once daily
A
Grade A74.8 ptsTop 5% of 2,523 stocks
Financial strength
81.3
Growth momentum
39.9
Price attractiveness
92.3

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

81.3
How much debt does it carry relative to equity?
Debt-to-equity ratio
15.8%
✓ Above median · Top 16.9% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
364.3%
✓ Above median · Top 31.1% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
14.9%
✓ Above median · Top 11.7% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
9.2%
✓ Above median · Top 15.2% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

39.9
How much did revenue grow in a year?
Revenue growth (YoY)
2.2%
✗ Below median · Top 61% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
4.2%
✗ Below median · Top 53.6% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-18.1%
✗ Below median · Top 70.3% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-5.4%
✗ Below median · Top 55.6% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

92.3
Is the price expensive relative to earnings?
P/E (price-to-earnings)
5.5x
✓ Above median · Top 3% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.51x
✓ Above median · Top 12.4% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15